IGXT (Mcap $31 M) 4x FDA approvals within 1 Year & Profitable this Year = Next ACAD
Hi Guys ..
Intelgenx launched their first drug Forfivo in October this will drive Intelgenx into Profitability this Year because of its very low burn-rate of around $1.2 Mil a year !
IGXT Submits NDA for Anti-Migraine Versafilm to FDA in March another 1x NDA filing for Erectile Dysfunction Versafilm and 2x ANDA filings expected in 1H 2013. Two Partnerships for Anti-Migraine and Erectile Dysfunction products is expected in 1H 2013 too which means more Cash for Intelgenx .Intelgenx has 9x Drugs in late stage which will be all on the Market within next 2-3 years .
IGXT has NO DEBT and Cash untill 2016 means enough to drive this Company into Profitability which is expected for this Year . Current Market Cap of just $31 M is really Brutally Underpriced .
IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Market Cap : $31 M
Cash: $3.5 M
Burn-Rate : $1.2 M a year
Price : $0.63
Shares Out : 50 M ( 20 M shares are held by Insiders & Institutions)
March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.
"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.